BenzingaOctober 12, 2026 at 5:20 AM NY15 Days Ago
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $460
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $455 to $460.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
